Dynavax aims to raise $60M; $125M NY genome center set to open in 2012;

@FierceBiotech: Gates' legendary discipline transforms vaccine effort. Item | Follow @FierceBiotech

@JohnCFierce: Inhibitex shares have more than doubled since their release discussing their interferon-free approach to hep C. Story | Follow @JohnCFierce

@RyanMFierce: Looks like Pfizer won't be axing as many R&D workers at Sandwich UK site as we thought. Retaining 650 workers. News | Follow @RyanMFierce

> Dynavax Technologies ($DVAX), a developer of a vaccine against hepatitis B, said it plans to raise $60 million in a stock sale. Report

> Galena Biopharma ($GALE) reported "positive" data today from mid-stage trials of its therapeutic vaccine called NeuVax for the treatment of breast cancer. The company said patients on its vaccine had a 48% reduced risk of cancer recurrence compared with the control group. Release

> Rexahn Pharmaceuticals' ($RNN) shares tanked on news that its Phase IIb study of Serdaxin for major depression didn't show efficacy compared with placebo. Item

> The New York Genome Center said it is set to open early next year, spending $125 million to establish one of the biggest genomic research hubs in the world. Report

Pharma News

@FiercePharma: GSK settles U.S. investigation for $3B. News | Follow @FiercePharma

> FDA panel approves outcomes claim for Vytorin. Item

> New Medicare code could boost Krystexxa sales. Story

> Off-label doses of Medtronic bone product risky, study shows. More

> Report: Teva, Ranbaxy team up to launch U.S. Lipitor copy. Article

> Is the U.K.'s cancer-drugs fund unfair? Piece

> Co-pay cards to hike drug costs $32B, report says. Article

And Finally... Brain scans show that fatty foods and sugary drinks can be addictive like narcotics. Article

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.